Skip to content

Comparison of Rainbow INVSENSOR00001 and Control SpHb Disposable Sensor Performance During Hemodilution

Comparison of Rainbow INVSENSOR00001 and Control SpHb Disposable Sensor Performance During Hemodilution

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03273166
Enrollment
82
Registered
2017-09-06
Start date
2017-08-29
Completion date
2017-09-18
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This study involves comparison of the performance of two SpHb sensors in subjects that undergo a hemodilution procedure. The sensors' performance will be assessed by comparison of the measured hemoglobin values against reference values obtained by a laboratory hematology analyzer. Blood samples will be collected from healthy volunteers who undergo a hemodilution procedure wherein blood is repeatedly sampled as the concentration of hemoglobin is reduced by administering intravenous fluids to the volunteer in a controlled manner.

Interventions

DEVICEINVSENSOR00001

This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.

DEVICEControl SpHb sensor

This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.

PROCEDUREHemodilution

This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Competent adults between the ages of 18 and 50 years of age * Must weigh a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall * BMI ≤ 35 unless the physician determines that a higher BMI is not due to morbid obesity, to safeguard subject safety during hemodilution * Must have a hemoglobin value ≥ 11 g/dL at time of screening, to safeguard subject safety during hemodilution * Baseline heart rate between 45 bpm and 85 bpm * CO value less than 2.0% FCOHb * Physical status of ASA I or II (American Society of Anesthesiology Class I; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) The ASA definition strictly applies to the systemic disease portion of the classification * Systolic BP less than or equal to 140 mmHg and Diastolic BP less than or equal to 90 mmHg * Able to read and communicate in English

Exclusion criteria

* Pregnancy or positive hCG test * Smokers (including e-cigarette users) * Subject has known drug or alcohol abuse. Subjects who uses recreational drugs * Subject has experienced a concussion or head injury with loss of consciousness within the last year * Any chronic bleeding disorders (i.e. hemophilia) * Any history of a stroke, myocardial infarction, or seizures * Any cancer or history of cancer (not including skin cancer) * Chronic neurological diseases (i.e. multiple sclerosis, Huntington's Disease) * Any cardiac dysrhythmias (i.e. atrial fibrillation)(without physicians clearance) * Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subject's level of consciousness * Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome * Subjects who have/are currently taking anticoagulant medication * Subjects who have taken opioid pain medication within 24 hours of start of study * Subjects who do not understand the study and the risks * Subjects having either signs or history of peripheral ischemia * Subjects who have had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery * Subjects that have symptoms of congestion, head colds, flu, or other illnesses * Subjects with claustrophobia, or generalized anxiety disorder * Subjects who have been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months * Subjects with chronic unresolved asthma, lung disease and respiratory disease * Subjects with allergies to lidocaine, latex, adhesives, or plastic * Subjects with heart conditions, insulin-dependent diabetes or uncontrolled hypertension * Subjects who have given vaginal delivery, had a pregnancy terminated, a miscarriage with hospitalization or had a c-section within the last 6 months * Subjects who intend on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study involving an arterial blood draw and/or arterial line placement * Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator)

Design outcomes

Primary

MeasureTime frameDescription
Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation1-5 hoursPerformance of the sensors will be determined by comparing the noninvasive hemoglobin measurement (SpHb) of the pulse oximeter sensors to the hemoglobin value obtained from a reference blood sample and calculating the accuracy root mean square(ARMS) value.

Countries

United States

Participant flow

Pre-assignment details

Fingers were not randomized to the two interventions. All participants received both interventions in the exact same manner.

Participants by arm

ArmCount
INVSENSOR00001
All subjects consented are enrolled into the test group and will receive the INVSENSOR00001 and the control sensor simultaneously on different fingers.
51
Total51

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawn prior to Completion31

Baseline characteristics

CharacteristicINVSENSOR00001
Age, Categorical
<=18 years
1 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
50 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Asian or Pacific Islander
3 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Black or African American
13 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Caucasian
17 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Hispanic
16 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Native American
2 Participants
Race/Ethnicity, Customized
Race/Ethnicity, Customized
Other
0 Participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
35 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 51
other
Total, other adverse events
2 / 51
serious
Total, serious adverse events
0 / 51

Outcome results

Primary

Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation

Performance of the sensors will be determined by comparing the noninvasive hemoglobin measurement (SpHb) of the pulse oximeter sensors to the hemoglobin value obtained from a reference blood sample and calculating the accuracy root mean square(ARMS) value.

Time frame: 1-5 hours

ArmMeasureValue (NUMBER)
INVSENSOR00001Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation0.9 g/dL
Control SpHb SensorComparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation0.9 g/dL

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026